James H. Stanker - Apr 1, 2022 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Chief Financial Officer
Signature
/s/ James H. Stanker by Michael B. Kirwan, as Attorney-in-Fact
Stock symbol
PCSA
Transactions as of
Apr 1, 2022
Transactions value $
$0
Form type
4
Date filed
4/11/2022, 05:54 PM
Previous filing
Jan 6, 2022
Next filing
Jul 5, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Restricted Stock Units Award $0 -248K -45.01% $0.00 303K Apr 1, 2022 Common Stock 248K $0.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan.
F2 The previous filing understated this number. This new total accurately reflects the cumulative total of Restricted Stock Units for the reporting person.